Loncar Cancer Valuation
| CNCR Etf | USD 8.42 0.50 5.61% |
At this time, the etf appears to be undervalued. Loncar Cancer Immuno secures a last-minute Real Value of $8.97 per share. The latest price of the etf is $8.42. Our model forecasts the value of Loncar Cancer Immuno from analyzing the etf fundamentals such as Price To Sales of 1.24 X, beta of 1.0, and Price To Earning of 24.63 X as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Loncar Cancer's price fluctuation is somewhat reliable at this time. Calculation of the real value of Loncar Cancer Immuno is based on 3 months time horizon. Increasing Loncar Cancer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Loncar etf is determined by what a typical buyer is willing to pay for full or partial control of Loncar Cancer Immunotherapy. Since Loncar Cancer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Loncar Etf. However, Loncar Cancer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.42 | Real 8.97 | Hype 8.42 |
The intrinsic value of Loncar Cancer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Loncar Cancer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Loncar Cancer Immunotherapy helps investors to forecast how Loncar etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Loncar Cancer more accurately as focusing exclusively on Loncar Cancer's fundamentals will not take into account other important factors: Loncar Cancer Total Value Analysis
Loncar Cancer Immunotherapy is currently forecasted to have valuation of 0 with market capitalization of 0, debt of , and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Loncar Cancer fundamentals before making equity appraisal based on enterprise value of the companyLoncar Cancer Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Loncar connotes not a very effective usage of assets in April.About Loncar Cancer Valuation
The etf valuation mechanism determines Loncar Cancer's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Loncar Cancer Immuno based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Loncar Cancer. We calculate exposure to Loncar Cancer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Loncar Cancer's related companies.The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Loncar Cancer Immunotherapy. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.